Liver | Lung | Melanoma, skin | Other Female Genital, Phase II
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Melanoma or Endometrial Carcinoma
Volunteers
Health Professionals
What is the purpose of this trial?
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will concurrently enroll patients with four distinct advanced malignancies in 5 separate tumor cohorts. The four cancers type are NSCLC and melanoma that are progressing on CPI treatment, CPI-naïve HCC, and treatment-naïve Endometrial.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- David A. Braun, MD, PhD
- Harriet Kluger, MD
- Jacquelyne Gaddy, MD, MSc, MSCR
- James Clune, MD
- Jeffrey Ishizuka, MD, DPhil
- Jeremy Kortmansky, MD
- Jill Lacy, MD
- Katelyn Scott
- Kelly Olino, MD, FACS
- Laura Van Metre Baum, MD, MPH
- Melissa Gambaccini
- Michael Cecchini, MD
- Michael Hurwitz, MD, PhD
- Pamela L. Kunz, MD
- Samantha Couillard
- Stacey Stein, MD
- Teresa White
- Thuy Tran, MD, PhD
- Vanna Dest
- Last Updated08/06/2024
- Study HIC#2000027272